S&P 500   3,156.34 (+0.47%)
DOW   28,050.39 (+0.50%)
QQQ   205.57 (+0.29%)
FB   196.59 (-2.80%)
GOOGL   1,340.21 (-0.30%)
AMZN   1,751.54 (+0.16%)
CGC   20.99 (+3.65%)
NVDA   221.12 (+1.74%)
MU   50.78 (+3.09%)
TSLA   359.17 (+1.83%)
T   38.35 (+0.47%)
AMD   41.29 (+4.61%)
PRI   136.53 (+0.80%)
NFLX   296.57 (-0.79%)
BAC   34.45 (+2.41%)
GILD   67.60 (-0.27%)
DIS   147.59 (+0.00%)
S&P 500   3,156.34 (+0.47%)
DOW   28,050.39 (+0.50%)
QQQ   205.57 (+0.29%)
FB   196.59 (-2.80%)
GOOGL   1,340.21 (-0.30%)
AMZN   1,751.54 (+0.16%)
CGC   20.99 (+3.65%)
NVDA   221.12 (+1.74%)
MU   50.78 (+3.09%)
TSLA   359.17 (+1.83%)
T   38.35 (+0.47%)
AMD   41.29 (+4.61%)
PRI   136.53 (+0.80%)
NFLX   296.57 (-0.79%)
BAC   34.45 (+2.41%)
GILD   67.60 (-0.27%)
DIS   147.59 (+0.00%)
S&P 500   3,156.34 (+0.47%)
DOW   28,050.39 (+0.50%)
QQQ   205.57 (+0.29%)
FB   196.59 (-2.80%)
GOOGL   1,340.21 (-0.30%)
AMZN   1,751.54 (+0.16%)
CGC   20.99 (+3.65%)
NVDA   221.12 (+1.74%)
MU   50.78 (+3.09%)
TSLA   359.17 (+1.83%)
T   38.35 (+0.47%)
AMD   41.29 (+4.61%)
PRI   136.53 (+0.80%)
NFLX   296.57 (-0.79%)
BAC   34.45 (+2.41%)
GILD   67.60 (-0.27%)
DIS   147.59 (+0.00%)
S&P 500   3,156.34 (+0.47%)
DOW   28,050.39 (+0.50%)
QQQ   205.57 (+0.29%)
FB   196.59 (-2.80%)
GOOGL   1,340.21 (-0.30%)
AMZN   1,751.54 (+0.16%)
CGC   20.99 (+3.65%)
NVDA   221.12 (+1.74%)
MU   50.78 (+3.09%)
TSLA   359.17 (+1.83%)
T   38.35 (+0.47%)
AMD   41.29 (+4.61%)
PRI   136.53 (+0.80%)
NFLX   296.57 (-0.79%)
BAC   34.45 (+2.41%)
GILD   67.60 (-0.27%)
DIS   147.59 (+0.00%)
Log in

NYSEAMERICAN:XXII - 22nd Century Group Stock Price, Forecast & News

$0.87
-0.05 (-5.45 %)
(As of 12/12/2019 02:27 PM ET)
Today's Range
$0.85
Now: $0.87
$0.91
50-Day Range N/A
52-Week Range
$0.70
Now: $0.87
$2.99
Volume863,504 shs
Average Volume1.47 million shs
Market Capitalization$109.07 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
22nd Century Group, Inc, a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM research cigarettes for use in independent clinical studies. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryCannabis
SectorMedical
Current SymbolNYSEAMERICAN:XXII
CUSIPN/A
CIKN/A
Phone+1-716-2701523

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees82
Market Cap$109.07 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive XXII News and Ratings via Email

Sign-up to receive the latest news and ratings for XXII and its competitors with MarketBeat's FREE daily newsletter.


22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions

What is 22nd Century Group's stock symbol?

22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."

How were 22nd Century Group's earnings last quarter?

22nd Century Group Inc (NYSEAMERICAN:XXII) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.07) EPS for the quarter. The biotechnology company earned $6.46 million during the quarter. View 22nd Century Group's Earnings History.

When is 22nd Century Group's next earnings date?

22nd Century Group is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for 22nd Century Group.

What price target have analysts set for XXII?

1 brokerages have issued 12-month price targets for 22nd Century Group's stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate 22nd Century Group's share price to reach $12.00 in the next year. This suggests a possible upside of 1,281.2% from the stock's current price. View Analyst Price Targets for 22nd Century Group.

What is the consensus analysts' recommendation for 22nd Century Group?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 22nd Century Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for 22nd Century Group.

What are Wall Street analysts saying about 22nd Century Group stock?

Here are some recent quotes from research analysts about 22nd Century Group stock:
  • 1. According to Zacks Investment Research, "22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. " (10/12/2019)
  • 2. Chardan Capital analysts commented, "We expect the Q1 rate to continue over the coming quarters. Cash at quarter end was $52 million, or almost 4 years of cash at the company’s current burn rate. However, investments in the hemp market, (see below), will lower the company’s cash balances modestly. Below the operating line, the company recognized a $3.0 million unrealized gain on the increase in value of its almost 1 million warrants of Aurora Cannabis. Aurora purchased the company’s stake in a combination of stock and warrants. All of the shares of Aurora were sold, but 22nd Century retained the warrants. In US dollars, Aurora trades at $8.60 per share and the exercise price of the warrants is $7.01 per share. The company is investing in the hemp market." (5/8/2019)

Has 22nd Century Group been receiving favorable news coverage?

Media stories about XXII stock have trended very negative on Thursday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. 22nd Century Group earned a news sentiment score of -3.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for 22nd Century Group.

Are investors shorting 22nd Century Group?

22nd Century Group saw a drop in short interest during the month of November. As of November 29th, there was short interest totalling 17,370,000 shares, a drop of 6.9% from the November 14th total of 18,660,000 shares. Based on an average trading volume of 1,430,000 shares, the short-interest ratio is currently 12.1 days. Approximately 14.6% of the company's stock are short sold. View 22nd Century Group's Current Options Chain.

Who are some of 22nd Century Group's key competitors?

What other stocks do shareholders of 22nd Century Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 22nd Century Group investors own include Cara Therapeutics (CARA), Canopy Growth (CGC), Novavax (NVAX), Cronos Group (CRON), Aurora Cannabis (ACB), Terra Tech (TRTC), Micron Technology (MU), Aurora Cannabis (ACBFF), NVIDIA (NVDA) and GW Pharmaceuticals PLC- (GWPH).

Who are 22nd Century Group's key executives?

22nd Century Group's management team includes the folowing people:
  • Mr. Henry Sicignano III, MBA, Pres, CEO & Director (Age 51)
  • Mr. John T. Brodfuehrer, CFO & Treasurer (Age 61)
  • Mr. Thomas L. James J.D., Esq., VP, Gen. Counsel & Sec. (Age 60)
  • James Vail, Director of Communications
  • Mr. James C. Morrison, Technical Advisor & Regulatory Affairs Consultant

Who are 22nd Century Group's major shareholders?

22nd Century Group's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.58%), Heritage Wealth Advisors (0.16%), Barclays PLC (0.05%), Cetera Advisors LLC (0.04%) and Metropolitan Life Insurance Co NY (0.01%). Company insiders that own 22nd Century Group stock include Clifford B Fleet and Thomas L James. View Institutional Ownership Trends for 22nd Century Group.

Which major investors are selling 22nd Century Group stock?

XXII stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Metropolitan Life Insurance Co NY and Barclays PLC. View Insider Buying and Selling for 22nd Century Group.

Which major investors are buying 22nd Century Group stock?

XXII stock was purchased by a variety of institutional investors in the last quarter, including Heritage Wealth Advisors and Cetera Advisors LLC. View Insider Buying and Selling for 22nd Century Group.

How do I buy shares of 22nd Century Group?

Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is 22nd Century Group's stock price today?

One share of XXII stock can currently be purchased for approximately $0.87.

How big of a company is 22nd Century Group?

22nd Century Group has a market capitalization of $109.27 million. 22nd Century Group employs 82 workers across the globe.View Additional Information About 22nd Century Group.

What is 22nd Century Group's official website?

The official website for 22nd Century Group is http://www.xxiicentury.com/.

How can I contact 22nd Century Group?

22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.


MarketBeat Community Rating for 22nd Century Group (NYSEAMERICAN XXII)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  553
MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote "Outperform" if you believe XXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XXII will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: What is Call Option Volume?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel